Literature DB >> 16548901

Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis.

Akihito Yokoyama1, Keiichi Kondo, Masamitsu Nakajima, Toshiharu Matsushima, Toru Takahashi, Masaharu Nishimura, Masashi Bando, Yukihiko Sugiyama, Yoshitaka Totani, Takeshi Ishizaki, Hidenori Ichiyasu, Moritaka Suga, Hironobu Hamada, Nobuoki Kohno.   

Abstract

OBJECTIVE: Circulating levels of KL-6, a high MW glycoprotein (MUC1 mucin), are elevated in a majority of patients with a number of interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). However, KL-6 levels vary from patient to patient. The aim of the present study was to determine whether the serum KL-6 level at the time of diagnosis predicts prognosis in IPF.
METHODS: The relationship between clinical variables and prognosis in 27 patients with IPF were analysed retrospectively. The diagnosis was made by histological examination (n = 16) or on clinical findings including high-resolution CT scanning (n = 11). All patients were followed up for at least 3 years. Variables such as age, FVC%, PaO(2) at rest, initial LDH level, C-reactive protein and KL-6 were used for analysis.
RESULTS: At the cut-off level determined by receiver operating characteristic curves, LDH and KL-6 showed a significant correlation with the patient's prognosis by univariate analysis. However, multivariate analysis revealed that only KL-6 was a predictor of prognosis. The patients were categorized by their serum KL-6 levels (as above or below the cut-off level of 1000 U/mL) and their survival estimated using the Kaplan-Meier method. The difference in median survival between the two groups was significant. The median survival of patients with low KL-6 was more than 36 months, whereas that of patients with high KL-6 was only 18 months.
CONCLUSION: These results suggest that initial evaluation of serum KL-6 level can predict survival in patients with IPF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16548901     DOI: 10.1111/j.1440-1843.2006.00834.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  86 in total

1.  Comparison of pulmonary thin section CT findings and serum KL-6 levels in patients with sarcoidosis.

Authors:  K Honda; F Okada; Y Ando; H Mori; K Umeki; H Ishii; J Kadota; M Ando; E Miyazaki; T Kumamoto
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

2.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

4.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

5.  T2 mapping of CT remodelling patterns in interstitial lung disease.

Authors:  Maria T A Buzan; Monika Eichinger; Michael Kreuter; Hans-Ulrich Kauczor; Felix J Herth; Arne Warth; Carmen Monica Pop; Claus Peter Heussel; Julien Dinkel
Journal:  Eur Radiol       Date:  2015-06-03       Impact factor: 5.315

6.  Allele-specific transactivation of matrix metalloproteinase 7 by FOXA2 and correlation with plasma levels in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Chunghyun Park; Yiliang Chen; Kevin F Gibson; Y Peter Di; Annie Pardo; Simon C Watkins; Augustine M K Choi; Moises Selman; Joseph Pilewski; Naftali Kaminski; Yingze Zhang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-20       Impact factor: 5.464

Review 7.  Molecular biomarkers in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Kevin K Brown; Harold R Collard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-09-26       Impact factor: 5.464

Review 8.  Pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Paul J Wolters; Harold R Collard; Kirk D Jones
Journal:  Annu Rev Pathol       Date:  2013-09-13       Impact factor: 23.472

Review 9.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

10.  Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.

Authors:  Subramaniam Pennathur; Anuradha Vivekanandan-Giri; Morgan L Locy; Tejaswini Kulkarni; Degui Zhi; Lixia Zeng; Jaeman Byun; Joao A de Andrade; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.